Article citationsMore>>

Medical Services Advisory Committee (2019) 1519—Tisagenlecleucel (CTL019) for Treatment of Refractory CD19-Positive Leukaemia and Lymphoma.

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top